Company Filing History:
Years Active: 2021
Title: The Innovations of Robert F. Stanley
Introduction
Robert F. Stanley is a notable inventor based in New York, NY (US). He has made significant contributions to the field of medical research, particularly in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). His work focuses on the development of compounds that inhibit the p21 protein (Cdc42/Rac)-activated kinase (PAK1).
Latest Patents
Robert F. Stanley holds a patent for PAK1 inhibitors and their uses. This patent outlines methods for treating AML and MDS using specific compounds that target PAK1. His innovative approach has the potential to improve treatment outcomes for patients suffering from these serious conditions.
Career Highlights
Stanley is affiliated with the Albert Einstein College of Medicine, where he conducts his research. His work has garnered attention in the scientific community, contributing to advancements in cancer treatment.
Collaborations
He has collaborated with esteemed colleagues, including Ulrich G. Steidl and Ashley M. Eckel, to further his research efforts. These collaborations have enhanced the scope and impact of his work in the field.
Conclusion
Robert F. Stanley's contributions to medical research, particularly through his patent on PAK1 inhibitors, highlight his role as an innovator in the fight against cancer. His work continues to inspire advancements in treatment methodologies.